Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography-tandem mass spectrometric method

Journal of Mass Spectrometry

Volumn 46, Issue 2, 2011, Pages 202-208

  Wang, Ling Zhi ^a   Lee, Lawrence Soon U ^b   Thuya, Win Lwin ^a   Soon, Gaik Hong ^b   Kong, Li Ren ^a   Nye, Pei Ling ^a   Deoon Lee, Edmund Jon ^c   Flexner, Charles ^d   Goh, Boon Cher ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

human; LC MS MS; plasma; raltegravir; raltegravir glucuronide

Indexed keywords

AVERAGE RECOVERY; CHROMATOGRAPHIC SEPARATIONS; CLINICAL TRIAL; COEFFICIENT OF VARIATION; CONSTANT FLOW RATES; FREEZE-THAW CYCLES; GLUCURONIDATION; GLUCURONIDES; GRADIENT ELUTION MODE; HEALTHY SUBJECTS; HUMAN; HUMAN PLASMAS; INTEGRASE; LC-MS/MS; ORAL DOSE; PLASMA SAMPLES; POSITIVE ELECTROSPRAY IONIZATION; PROTEIN PRECIPITATION; RALTEGRAVIR; ROOM TEMPERATURE; RUNTIMES; SIMULTANEOUS DETERMINATIONS; TANDEM MASS SPECTROMETRIC;

ACETONITRILE; DISEASES; ELECTROSPRAY IONIZATION; LIQUID CHROMATOGRAPHY; LIQUIDS; MASS SPECTROMETERS; MASS SPECTROMETRY; PLASMA (HUMAN); POSITIVE IONS;

PLASMAS;

ACETONITRILE; ANTIRETROVIRUS AGENT; DRUG METABOLITE; GLUCURONIDE; RALTEGRAVIR; RALTEGRAVIR GLUCURONIDE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DETERMINATION; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; NORMAL HUMAN; PRECIPITATION; PRIORITY JOURNAL; ROOM TEMPERATURE; TANDEM MASS SPECTROMETRY;

AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; GLUCURONIDES; HUMANS; PYRROLIDINONES; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 79951670921     PISSN: 10765174     EISSN: 10969888     Source Type: Journal    
DOI: 10.1002/jms.1874     Document Type: Article

References (24)

1. Y. Pommier, A. A. Johnson, C. Marchand,. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 2005, 4, 236.
2. J. D. Croxtall, K. A. Lyseng-Williamson, C. M. Perry,. Raltegravir. Drugs 2008, 68, 131.
3. J. L. Lennox, E. Dejesus, D. S. Berger, A. Lazzarin, R. B. Pollard, J. V. Ramalho Madruga, J. Zhao, H. Wan, C. L. Gilbert, H. Teppler, A. J. Rodgers, R. J. Barnard, M. D. Miller, M. J. Dinubile, B. Y. Nguyen, R. Leavitt, P. Sklar, STARTMRK Investigators. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J. Acquir. Immune Defic. Syndr. 2010, 55, 39.
4. R. T. Steigbigel, D. A. Cooper, P. N. Kumar, J. E. Eron, M. Schechter, M. Markowitz, M. R. Loutfy, J. L. Lennox, J. M. Gatell, J. K. Rockstroh, C. Katlama, P. Yeni, A. Lazzarin, B. Clotet, J. Zhao, J. Chen, D. M. Ryan, R. R. Rhodes, J. A. Killar, L. R. Gilde, K. M. Strohmaier, A. R. Meibohm, M. D. Miller, D. J. Hazuda, M. L. Nessly, M. J. DiNubile, R. D. Isaacs, B. Y. Nguyen, H. Teppler,. Raltegravir with optimized background therapy for resistance HIV-1 infection. N. Engl. J. Med. 2008, 359, 339.
5. J. Cocohoba, B. J. Dong,. Raltegravir: the first HIV integrase inhibitor. Clin. Ther. 2008, 30, 1747.
6. K. Kassahun, I. McIntosh, D. Cui, D. Hreniuk, S. Merschman, K. Lasseter, N. Azrolan, M. Iwamoto, J. A. Wagner, L. A. Wenning,. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the HIV-1 integrase enzyme. Drug Metab. Dispos. 2007, 35, 1657.
7. C. Tommasi, E. Nicastri, A. L. Gallo, M. Tempestilli, R. Bellagamba, R. Fezza, J. Ivanovic, L. P. Pucillo, P. Narciso,. Raltegravir and darunavir plasma pharmacokinetics in HIV-1-infected patients with advanced liver disease (abstract #10), 11th International Workshop on Clinical Pharmacology of HIV Therapy, Sorrento, Italy, April 7-9, 2010.
8. L. A. Wenning, A. S. Petry, J. T. Kost, B. Jin, S. A. Breidinger, I. DeLepeleire, E. J. Carlini, S. Young, T. Rushmore, F. Wagner, N. M. Lunde, F. Bieberdorf, H. Greenberg, J. A. Stone, J. A. Wagner, M. Iwamoto,. Pharmacokinetics of RAL in individuals with UGT1A1 polymorphisms. Clin. Pharmacol. Ther. 2009, 85, 623.
9. L. Goldwirt, A. Barrail-Tran, M. Da Cruz, A. M. Taburet, V. Furlan,. Quantification of raltegravir (MK0518) in human plasma by high-performance liquid chromatography with photodiode array detection. J. Chromatogr. B 2010, 878, 456.
10. J. A. Talameh, N. L. Rezk, A. D. M. Kashuba,. Quantifying the HIV-1 integrase inhibitor raltegravir in female genital tract secretions using high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B 2010, 878, 92.
11. S. Notari, C. Tommasi, E. Nicastri, R. Bellagamba, M. Tempestilli, L.P. Pucillo, P. Narciso, P. Ascenzi,. Simultaneous determination of maraviroc and raltegravir in human plasma by HPLC-UV. IUBMB Life 2009, 61, 470.
12. A. D'Avolio, L. Baietto, M. Siccardi,. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther. Drug Monit. 2008, 30, 662.
13. R. M. Lopez, J. L. Blanco, M. Martin, J. Mallolas, D. Guill, J. M. Gatell, M. Brunet,. Quantification of the HIV-integrase inhibitor raltegravir in human plasma by HPLC with fluorescence detection, 11th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Canada, October 3-8, 2009.
14. J. M. Poirier, P. Robidou, P. Jaillon,. Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B 2008, 867, 277.
15. S. A. Merschman, P. T. Vallano, L. A. Wenning, B. K. Matuszewski, E. J. Woolf,. Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS. J. Chromatogr. B 2007, 857, 15.
16. S. Quaranta, C. Woloch, A. Paccou, M. Giocanti, C. Solas, B. Lacarelle,. Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples. Ther. Drug Monit. 2009, 31, 695.
17. J. F. Jourdil, M. Bartoli, S. Stanke-Labesque,. Lack of specificity for the analysis of raltegravir using online sample clean-up liquid chromatography-electrospray tandem mass spectrometry. J. Chromatogr. B 2009, 877, 15.
18. A. Fayet, A. Beguin, B. Zanolari, S. Cruchon, N. Guignard, A. Telenti, M. Cavassini, H. F. Gunthard, T. Buclin, J. Biollaz, B. Rochat, L. A. Decosterd,. A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: raltegravir, maraviroc, darunavir, and etravirine. J. Chromatogr. B 2009, 877, 1057.
19. R. ter Heine, M. J. X. Hillebrand, H. Rosing, E. C. van Gorp, J. W. Mulder, J. H. Beijnen, A. D. Huitema,. Quantification of the HIV-integrase inhibitor raltegravir and detection of its main metabolite in human plasma, dried blood spots and peripheral blood mononuclear cell lysate by means of high-performance liquid chromatography-tandem mass spectrometry. J. Pharmaceut. Biomed. 2009, 49, 451.
20. M. Takahashi, M. Konishi, Y. Kudaka, N. Okudaka, A. Hirano, N. Terahata, K. Banno, T. Kaneda,. A conventional LC-MS method developed for the determination of plasma raltegravir concentrations. Biol. Pharm. Bull. 2008, 31, 1601.
21. European Union Quality Guidance ICH. Available at:.
22. Guidance for Industry-Bioanalytical Method Validation. Available at:.
23. B. K. Matuszewski, M. L. Constanzer, C. M. Chavez-Eng,. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003, 75, 3029.
24. K. Kassahun, I. McIntosh, D. Cui, D. Hreniuk, S. Merschman, K. Lasseter, N. Azrolan, M. Iwamoto, J. A. Wager, L. A. Wenning,. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab. Dispos. 2007, 35, 1657.